UA87009C2 - Композиции, которые содержат гибридные белки-аналоги glp-1 - Google Patents

Композиции, которые содержат гибридные белки-аналоги glp-1

Info

Publication number
UA87009C2
UA87009C2 UAA200706803A UAA200706803A UA87009C2 UA 87009 C2 UA87009 C2 UA 87009C2 UA A200706803 A UAA200706803 A UA A200706803A UA A200706803 A UAA200706803 A UA A200706803A UA 87009 C2 UA87009 C2 UA 87009C2
Authority
UA
Ukraine
Prior art keywords
glp
fusion protein
fusion
formulations
protein formulations
Prior art date
Application number
UAA200706803A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вольфганг Глезнер
мл. Милликан Рон Ли
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA87009C2 publication Critical patent/UA87009C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к стойкой растворимой композиции, которая содержит гибридный белок GLP-1-Fc при рН в пределах от приблизительно рН 6 до приблизительно рН 8,5. Аналоги являются слитыми с конкретными производными IgG4-Fc. Эти композиции обеспечивают неожидаемую и значительно высшую химическую стойкость в случае сравнения с гибридными белками GLP-1-Fc при рН за пределами описанных диапазонов. Композиции, которые содержат гибридный белок GLP-1-Fc, полезны при лечении диабета, ожирения, синдрома разраженной толстой кишки и других состояний, благотворным для которых было бы снижение уровней глюкозы в плазме, угнетение подвижной функции желудка и/или перистальтики кишечника и угнетение опорожнения желудка и/или кишечника или угнетение потребления пищи.
UAA200706803A 2004-12-22 2005-12-15 Композиции, которые содержат гибридные белки-аналоги glp-1 UA87009C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64169004P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
UA87009C2 true UA87009C2 (ru) 2009-06-10

Family

ID=36123207

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200706803A UA87009C2 (ru) 2004-12-22 2005-12-15 Композиции, которые содержат гибридные белки-аналоги glp-1

Country Status (23)

Country Link
US (1) US20090232807A1 (ru)
EP (2) EP2168982A1 (ru)
JP (1) JP2008525452A (ru)
KR (1) KR100879662B1 (ru)
CN (1) CN101044162B (ru)
AT (1) ATE435235T1 (ru)
AU (1) AU2005319432A1 (ru)
BR (1) BRPI0519393A2 (ru)
CA (1) CA2589647A1 (ru)
CY (1) CY1109269T1 (ru)
DE (1) DE602005015257D1 (ru)
DK (1) DK1831252T3 (ru)
EA (1) EA011166B1 (ru)
ES (1) ES2326906T3 (ru)
HK (1) HK1107570A1 (ru)
IL (1) IL183285A0 (ru)
MX (1) MX2007007565A (ru)
NO (1) NO20073372L (ru)
PL (1) PL1831252T3 (ru)
PT (1) PT1831252E (ru)
SI (1) SI1831252T1 (ru)
UA (1) UA87009C2 (ru)
WO (1) WO2006068910A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
UA97673C2 (ru) * 2007-07-10 2012-03-12 Эли Лилли Энд Компани КОМПОЗИЦИЯ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА GLP-1Fc
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
ES2528496T3 (es) * 2010-05-17 2015-02-10 Betta Pharmaceuticals Co., Ltd. Nuevos análogos de péptido similar a glucagón, composición, y métodos de uso
CN102533655A (zh) * 2010-12-21 2012-07-04 青岛黄海制药有限责任公司 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
EP2654767A4 (en) 2010-12-22 2014-05-21 Amylin Pharmaceuticals Inc GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
CN104173275A (zh) * 2013-05-21 2014-12-03 深圳翰宇药业股份有限公司 度拉鲁肽注射剂及其制备方法
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
CA2944138C (en) * 2014-03-31 2023-06-20 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
US20160137712A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion Proteins With Dual Receptor Agonist Activities
US10485870B2 (en) 2015-02-11 2019-11-26 Gmax Biopharm Llc. Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
JOP20190177A1 (ar) * 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
MA50798A (fr) 2017-11-21 2020-09-30 Lilly Co Eli Procédés d'utilisation et compositions contenant du dulaglutide
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20220143187A1 (en) 2019-03-15 2022-05-12 Eli Lilly And Company Preserved formulations
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
US20210187077A1 (en) * 2019-12-23 2021-06-24 Idaho State University GLP-1 Agonist Conjugates for Sustained Glycemic Control
CN116478298A (zh) * 2021-12-31 2023-07-25 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
CZ306180B6 (cs) * 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
PT1641823E (pt) * 2003-06-12 2011-11-08 Lilly Co Eli Proteínas de fusão de análogos de glp-1

Also Published As

Publication number Publication date
CN101044162A (zh) 2007-09-26
DK1831252T3 (da) 2009-10-05
BRPI0519393A2 (pt) 2009-01-20
EA200701364A1 (ru) 2007-10-26
EP1831252A1 (en) 2007-09-12
IL183285A0 (en) 2007-09-20
KR20070089187A (ko) 2007-08-30
ES2326906T3 (es) 2009-10-21
AU2005319432A1 (en) 2006-06-29
EP1831252B1 (en) 2009-07-01
MX2007007565A (es) 2007-07-24
ATE435235T1 (de) 2009-07-15
JP2008525452A (ja) 2008-07-17
KR100879662B1 (ko) 2009-01-20
NO20073372L (no) 2007-07-16
PL1831252T3 (pl) 2009-11-30
DE602005015257D1 (ru) 2009-08-13
CY1109269T1 (el) 2014-07-02
HK1107570A1 (en) 2008-04-11
EP2168982A1 (en) 2010-03-31
US20090232807A1 (en) 2009-09-17
WO2006068910A1 (en) 2006-06-29
SI1831252T1 (sl) 2009-12-31
EA011166B1 (ru) 2009-02-27
CN101044162B (zh) 2010-10-27
CA2589647A1 (en) 2006-06-29
PT1831252E (pt) 2009-09-17

Similar Documents

Publication Publication Date Title
UA87009C2 (ru) Композиции, которые содержат гибридные белки-аналоги glp-1
TW200507870A (en) GLP-1 analog fusion proteins
NO20076415L (no) GLP-1 pegylerte forbindelser
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
NZ515902A (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes
WO2007044591A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
WO2006042152A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
RS20060320A (en) Substituted indazole-o-glucosides
SG130189A1 (en) Substituted indole-o-glucosides
WO2005089483A3 (en) Low glycemic sweeteners and products made using the same
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
WO2005113606A3 (en) Fgf-21 fusion proteins
GEP20125565B (en) Lactam compounds and their pharmaceutical use
DE60110054D1 (en) Cardioprotektive phosphonate
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2003024965A3 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
WO2008155900A1 (ja) 糖鎖付加glp-1ペプチド
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
EP1561472A4 (en) SOLID PREPARATION
AU2002354269A1 (en) Pharmaceutical and foodstuff products comprising deuterium for the treatment of diabetes and methods for production thereof
WO2006044753A3 (en) Chemical compounds
AU2001260077A1 (en) Microfiltration using activated carbon
WO2003024946A3 (en) Oxamate derivatives containing a variously substituted nitrogen heterocycle
Mulakala et al. Toward the Transition State: Further Docking Studies on Family 47 Alpha-1, 2-Mannosidases